Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health

Contributed by: GlobeNewswire

Tags

Biotechnology

More Like This

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Topflight Pharma Development Veteran Joins Synendos

Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)